HDL Cholesterol Reduction during Rosiglitazone and Fenofibrate Treatment in a Type 2 Diabetes Mellitus Patient with Dyslipidemia / 대한진단검사의학회지
The Korean Journal of Laboratory Medicine
;
: 17-19, 2010.
Article
in Korean
| WPRIM
| ID: wpr-121792
ABSTRACT
Thiazolidinediones (TZD), which are widely used as insulin sensitizers, and fibrates, which are lipid-lowering drugs, are used in the treatment of dyslipidemia that commonly accompanies diabetes. Several reports suggest elevated levels of high-density lipoprotein (HDL) cholesterol, but the paradoxical reduction of HDL cholesterol level during single or combined TZD and fibrate therapies has been occasionally reported. Herein, we report a case of paradoxical decrease in HDL cholesterol and apolipoprotein A-1 levels during rosiglitazone and fenofibrate treatment for the first time in Korea. The patient was a 56-yr-old man presenting with type 2 diabetes mellitus and dyslipidemia. His HDL cholesterol and apolipoprotein A-1 levels returned to normal after the cessation of fenofibrate therapy. Since diabetes is an established risk factor of cardiovascular diseases, low HDL cholesterol can be a key cause of concern for patients with diabetes. Therefore, HDL cholesterol level should be determined before and after starting TZD and/or fibrate therapy in diabetic patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fenofibrate
/
Apolipoprotein A-I
/
Thiazolidinediones
/
Diabetes Mellitus, Type 2
/
Dyslipidemias
/
Cholesterol, HDL
/
Hypolipidemic Agents
Limits:
Humans
/
Male
Language:
Korean
Journal:
The Korean Journal of Laboratory Medicine
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS